US2015183770A1PendingUtilityA1
5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
Est. expiryAug 21, 2025(expired)· nominal 20-yr term from priority
Inventors:Wilhelm AmbergAstrid NetzAndreas KlingMichael OchseUdo LangeAndreas HauptFrancisco Javier Garcia-LadonaWolfgang Wernet (Deceased)
C07D 417/04C07D 233/70A61P 25/00C07D 249/14C07D 231/38C07D 405/04C07D 409/04C07D 413/04C07D 233/88A61P 25/28
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.
Claims
exact text as granted — not AI-modified1 . A 5-ring heteroaromatic compound of general formula
and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursor (“prodrugs”) thereof, wherein the stated radicals have the following definitions:
W: is a radical of general formula W 1 or W 2
wherein
A: is NO 2 , NH 2 , CN, CF 3 , OCF 3 , CHF 3 , OCHF 2 , COOH, O—CH 2 —COOH, halogen, SH, or in each case optionally substituted O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, —O—CO—C 1 -C 6 alkyl, —O—CO aryl, —O—CO hetaryl, —O—COO—C 1 -C 6 alkyl, or in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 4 alkylene-hetaryl, or C 1 -C 4 alkylene-aryl, of
in each case optionally substituted O—R A 1 , CO—R A 1 , S——R A 1 , SO——R A 1 , CO—O—R A 1 , NR A 4 —CO—O—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , NR A 4 , —CO—R A 1 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , SO 2 —NR A 2 R A 3 , or CO—NR A 2 R A 3 ;
R A 1 : is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 2 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 4 alkylene-aryl, C 2 -C 6 alkenylene-aryl, C 1 -C 6 alkylene-hetaryl;
R A 2 : is hydrogen, or in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, SO 2 − C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 —C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
R A 3 : is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkylene-C 3 -C 2 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 —C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
or the radicals R A 2 and R A 3 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle which is optionally substituted in each case, which may contain one, two, or three further heteroatoms, which may be different or the same, from the group O, N, S, wherein two radicals substituted on this heterocycle together may optionally form a 3- to 7-membered anellated, saturated, unsaturated, or aromatic carbocycle or heterocycle, wherein the heterocycle may contain up to three heteroatoms O, N, S which may be different or the same, and wherein the cyclic compound thus formed may optionally be substituted, or a further 3- to 7-membered, optionally substituted cyclic compound may be condensed thereon;
R A 4 : is hydrogen, or in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl, C 1 -C 4 alkylene-aryl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl; hetaryl;
B: hydrogen, or is defined as for radical A, independently of radical A, or two of the radicals A, B, or R w 1 in each case independently form, together with the attached C atoms, a 3- to 7-membered, saturated, unsaturated, or aromatic carbocycle which is optionally substituted in each case, or a 3- to 7-membered saturated, unsaturated, or aromatic heterocycle which in each case is optionally substituted and which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S, wherein in each case two radicals substituted on this carbocycle or heterocycle together may optionally form a 3- 7-membered anellated, saturated, unsaturated, or aromatic carbocycle or heterocycle, wherein the heterocycle may contain up to three heteroatoms O, N, S which may be different or the same, and wherein the cyclic compound that is formed may optionally be substituted;
R w 1 : is hydrogen, OH, halogen, NO 2 , NH 2 , CN, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , OCH 2 F,
or in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, C 1 -C 6 thioalkyl, aryl hetaryl, O—C 1 -C 6 alkyl, O-benzyl, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, pyrrolidinyl, piperidinyl, morpholinyl, CO—C 1 -C 6 alkyl, SO 2 —C 1 -C 6 alkyl, CO-aryl, SO 2 -aryl, CO—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 4 alkylene-aryl, SO-aryl, CONH 2 , CONH—C 1 -C 6 alkyl, SO 2 NH—C 1 -C 6 alkyl, CON—(C 1 -C 6 alkyl) 2 , SO 2 N—(C 1 -C 6 alkyl) 2 , NH—SO 2 —C 1 -C 6 alkyl, or NH—CO—C 1 -C 6 alkyl;
and/or optionally, preferably with the condition that when W=W1, R, or B is not an optionally substituted N-pyrrolidinyl radical in the 4-position (para position) with respect to the coupling position with Q;
D: is hydrogen or is defined as for radical A, independently of radical A;
Q: is a radical of general formula Q1
having the indices
a=0-4 (i.e., an integer equal to 0, 1, 2, 3, or 4)
b=0,1 (i.e., an integer equal to 0 or 1)
c=0-4 (i.e., an integer equal to 0, 1, 2, 3, or 4)
wherein the sum of a, b, and c is at least 1, and 2, 3, 4, and no greater than 5, and is equal to 0, 1, 2, 3, 4, or 5 for the case; X=N, Y=CR 4 , Z=CR 6 ;
R Q 1 , R Q 2 , R Q 3 , R Q 4 independently stand for:
hydrogen, halogen, OH, far
in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl, aryl, C 1 -C 4 alkylene-aryl, hetaryl, or C 1 -C 4 alkylene-hetaryl, or
in each case two radicals R Q 1 and R Q 2 or R Q 3 and R Q 4 independently form together with the respective C atom a 3- to 7-membered, in each case optionally substituted, saturated or unsaturated carbocycle or heterocycle, wherein the heterocycle may contain one, two, or three heteroatoms selected from the group comprising O, N, and/or S;
V Q : is in each case optionally substituted —CO—, —CO—NR Q 5 —, —NR Q 5 —CO—, —O—, —S—, −SO—, —SO 2 —, —SO 2 —NR Q 5 —, —NR Q 5 —SO 2 —, —CS—, —CS—NR Q 5 —, —NR Q 5 —CS—, —CS—O—, —CO—O—, —O—CO—, —O—, ethynylene, —C(═CR Q 6 R Q 7 )—, —CR Q 6 ═CR Q 7 —, —NR q 5 —CO—NR Q 5 *—, —O—CO—NR Q 5 —, or —NR Q 5 —;
R Q 5 , R Q 5 * independently stand for:
hydrogen or
in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, C 2 -C 6 alkyenyl, C 3 -C 12 alkynyl, CO—C 1 -C 6 alkyl, CO—O—C 1 -C 6 alkyl, SO 2 —C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, C 1 -C 4 alkylene-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-aryl, CO-aryl, SO 2 -aryl, hetaryl, CO-hetaryl, or SO 2 —C 1 -C 4 alkylene-aryl;
R Q 6 , R Q 7 independently stand for:
Hydrogen, OH, or
in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl, aryl, C 1 -C 4 alkylene-aryl, hetaryl, or C 1 -C 4 alkylene-hetaryl;
R 1 , R 2 independently stand for:
hydrogen, OH, CN, or
in each case optionally substituted C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, C 5 -C 6 cycloalkyl, O—C 3 -C 7 cycloalkyl, aryl, hetaryl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, O-aryl, O—C 1 -C 4 alkylene-aryl, O-hetaryl, O—C 1 -C 4 alkylene-hetaryl, CO—C 1 -C 6 alkyl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 C 1 -C 4 alkylene-aryl, OCO—C 1 -C 6 alkyl, OCO-aryl, OCO-hetaryl, OCO—C 1 -C 4 alkylene-aryl, OCO—C 1 -C 4 alkylene-hetaryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, or SO 2 —C 1 -C 4 alkylene-aryl, or
R 1 and R 2 to with the nitrogen form a 5- to 7-membered saturated or unsaturated heterocycle optionally substituted in each case, which may contain one, two, or three. further heteroatoms, which may be inherent or the same, from the group O, N, S, wherein in each case two radicals substituted on this carbocycle or heterocycle together may optionally form a 3- to 7-membered anellated, saturated, unsaturated, or aromatic carbocycle or heterocycle which is optionally substituted in each case, wherein the heterocycle may contain up to three heteroatoms, which may be different or the same, selected from the group comprising O, N, and S, and wherein the cyclic compound that is formed may optionally be substituted;
R 3 is a free electron pair or hydrogen;
X, Y, Z in each case have the following meanings:
X=N, Y=CR 4 , Z=CR 6 , or
X=C, Y=NR 6 , Z=CR 6 , or
X=N, Y=CR 4 , Z=NR 7 , or
X=N, Y=N, Z=CR 6 , or
X=N, Y=CR 6 , Z=N;
R 4 , R 6 in each case independently stand for a radical, selected from groups 1.), 3.), 4.) 5.), or 6.), which may be the same or different, and
R 5 , R 7 in each case in stand for a radical selected from groups 2.). 3.), 4.), or 5.), which may be the same or different;
1.) Hydrogen, NO 2 , NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , COOH, O—CH 2 —COOH, halogen, or
in each case optionally substituted C 1 -C 10 alkyl, C 2 -C 10 alkyenyl, C 2 -C 10 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, C 1 -C 6 alkylene-O-aryl, COO—C 1 -C 6 alkyl, or C 1 -C 4 alkylene-COO—C 1 -C 6 alkyl, or in each case optionally substituted O—R Z,Y 4 , S—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—OR Z,Y 5 , CO—R Z,Y 5 , NR Z,Y 7 —CO—O—R Z,Y 5 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 , SO—R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ;
2.) A free electron pair or hydrogen, CH 2 —CF 3 , CH 2 —CHF 2 , in each case optionally substituted C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 alkylene-O-aryl, COO—C 1 -C 6 alkyl, or C 1 -C 4 alkylene-COO—C 1 -C 6 alkyl, or in each case optionally substituted CO—O—R Z,Y 5 , CO—R Z,Y 5 , SO 2 —R Z,Y 5 , SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 5 , or CO—NR Z,Y 6 R Z,Y 7 ;
3.) Phenyl, 1-naphthyl, or 2-naphthyl, which in each case are or may be substituted with one, two, or three radicals selected from R Z,Y 1 , R Z,Y 2 and R Z,Y 3 , wherein
R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 (in each case, independently represent a substituent from the following group:
Hydrogen, NO 2 , NH 2 , OH, CN, CF CHF 2 , OCF 3 , OCHF 2 , COOH, O—CH 2 —COON, SH, halogen, or
in catch case optionally substituted aryl, hetaryl heterocycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
O—R Z,Y 4 , S—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—OR Z,Y 5 , NR Z,Y 7 —CO—O—R Z,Y 5 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , NR Z,Y 7 —CO—NR Z,Y 5 , SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —N Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ; or
in each case two of the radicals selected from the group comprising R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 form, together with the ring atoms bearing these substituents, a 3- to 7-membered saturated or unsaturated carbocycle which in each case is optionally substituted, or a saturated or unsaturated 3- to 7-membered heterocycle which in each case is optionally substituted and which may contain one, two, or three further heteroatoms, which may be different or the same, selected From the group comprising O, N, and S, wherein optionally in each case two radicals substituted on this carbocycle or heterocycle together may form a 3- to 7-membered, anellated, saturated, unsaturated, or aromatic carbocycle, or heterocycle, wherein the heterocycle may contain one, two, or three, heteroatoms, which may be different: or the same, comprising O, N, and S, and wherein the cyclic compound thus; formed may optionally be substituted, and/or a further 3- to 7-membered, optionally substituted cyclic compound may be condensed thereon;
R Z,Y 4 is in each case optionally substituted C 2 -C 6 alkenyl, C 4 -C 6 alkynyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, C 1 -C 4 alkylene-hetaryl, hetaryl, C 1 -C 4 alkylene-aryl, aryl, or
C 1 -C 6 alkyl, which in each case is optionally substituted with a substituent selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl), or optionally substituted N(C 1 -C 6 alkyl) 2 ;
R Z,Y 5 is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, or C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, dioxymethylenephenyl, benzofuranyl, dihydrobenzofuranyl, or indanyl, or aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted with substituents independently selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl) or optionally substituted N(C 1 -C 6 alkyl) 2 , and COOH, O—CH 2 —COOH, SH, or in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 4 alkylene-hetaryl, or C 1 -C 4 alkylene-aryl, or in each case optionally substituted
O—R A 1 , CO—R A 1 , S—R A 1 , SO—R A 1 , CO—O—R A 1 , NR A 4 —CO—O—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , NR A 4 —CO—R A 1 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , SO 2 —NR Z 2 R A 3 , or CO—NR A 2 , R A 3 ,
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 —C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
R Z,Y 7 is hydrogen or in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 —C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
or the radicals R Z,Y 6 and R Z,Y 7 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle which is optionally substantiated in each case and which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S; and in each case two radicals substituted on this heterocycle together may optionally form a 3- to 7-membered anellated, saturated, unsaturated, or aromatic carbocycle or heterocycle, wherein the heterocycle may contain one, two, of three heteroatoms, which may be different or the same selected from the group comprising O, N, and S, and the cyclic compound thus formed may
optionally be substituted, or a further 3- to 7-membered, optionally substituted cyclic compound may be condensed thereon;
4.) A 5- or 6-membered, in each case optionally substituted, aromatic heterocycle which may contain one, two, or three heteroatoms which may be different or the same, selected from the group comprising O, N, and S, and which in each case may be substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 , where R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 independently have the meanings given above under 3.);
5.) A C 5 -C 15 bi- or tricyclic saturated hydrocarbon radical which in each case is optionally substituted;
6.) R 4 and R 6 together with X and Y form, optionally substituted in each case, a C 6 -C 10 -membered saturated, unsaturated, or aromatic carbocycle, preferably a benzo radical, which may be substituted in each case with one, two, or three radicals which in each case are independently selected from R Z,Y 8 ;
R Z,Y 8 : hydrogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , COOH, O—CH 2 —COOH, SH, halogen, or
in each case optionally substituted aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alky, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted O—R Z,Y 4 , S—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—OR Z,Y 5 , NR Z,Y 7 —CO—O—R Z,Y 5 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 5 R Z,Y 7 ,
optionally preferably with one, two, or three of the conditions selected from the group comprising conditions (i), (ii), and (iii) listed below:
(i) with the condition (i) that when R 4 and R 6 have the meanings given for group 6.), the radicals A, B, Q, R Z 1 , and R Z 2 are defined as follows:
A is located in W1 in the 2-position as indicated and stands for NH 2 , OCF 3 , OCHF 2 , O—CH 2 —COOH, O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, or O—R A 1 , CO—R A 1 , S—R A 1 , SO—R A 1 , SO 2 —R A 1 , SO 2 —NR A 2 R A 3 ;
B is located in W 1 in the 6-position and stands for halogen, CN, CF 3 , —CHF 2 , OCF 3 , OCHF 2 , or in each case optionally substituted C 1 -C 6 alkyl or C 2 -C 6 alkenyl, O—CH 2 —COO—R Z 1 , —O—R A 1 , S—R A 1 , NR A 2 R A 3 , —NR A 1 —CO—R A 1 , or —CO—NR A 2 R A 3 ; NR A 4 —SO 2 —R A 1 ; or B together with R Q 1 forms one of the radicals—(CH 2 ) 3 —, —O CH 2 —O—, —O—(CH 2 ) 2 —O—, —CH═CH—CH═CH—, —O—(CH 2 ) 2 —, —(CH 2 ) 2 —O—;
Q is —CR Q 1 R Q 2 ;
R Q 1 , R Q 2 independently stand for:
hydrogen, halogen, optionally substituted C 1 -C 6 alkyl;
ii) with the condition (ii) that when W=W 1 , R w 1 or B is not an optionally substituted N-pyrrolidinyl radical in the 4-position (pare position) with respect to the coupling position with Q;
iii) with the condition (iii) that the sum of a, b, and c 1, 2, 3, 4 or 5 when X=N, Y=CR 4 , Z=CR 6 .
2 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 R A 2 R A 3 R A 4 , B, Rw 1 , D, Q, a b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , X, Y, Z, unless stated otherwise below, have the same meaning as in claim 1 , and the radicals below have the following definitions:
R 4 , R 6 in each case independently stand for a radical selected from groups 1.), 3.), 4.), or 5.), which may be the same or different, and
R 5 , R 7 in each case independently stand for a radical selected from groups 2.), 3.), 4.), or 5.), which may be the same or different,
wherein groups 1.)-5.) in each case have the meanings stated in claim 1 .
3 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, R 1 , R 2 , R 3 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R ZY 1 , R ZY 2 , R ZY 3 , R ZY 4 , R ZY 5 , R ZY 6 , R ZY 7 , R ZY 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
Q: Formula Q1 is the sum of a, b, and c and is equal to 1, 2, or 3;
R Q 1 , R Q 2 , R Q 3 , R Q 4 independently stand for:
hydrogen, halogen, OH, or optionally substituted C 1 -C 6 alkyl;
V Q : is —CO—, —CO—NR Q 5 —, —NR Q 5 —CO—, —O—, —S—;
R Q 5 : is hydrogen, CH 3 .
4 . A 5-ring heteroaromatic compound of general formula I according to claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric for thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, R 1 , R 2 , R 3 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
Q: in Formula Q1 is the sum of a=1 and b=c=O;
R Q 1 , R Q 2 independently stand for:
hydrogen, halogen, OH, or optionally substituted C 1 -C 6 alkyl.
5 . A 5-ring heteroaromatic compound of general formula I according to claim 1 and/or corresponding enantiomeric, diastereormeric, and/or tautormeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein tile Q, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
W: stands for a radical of general formula W1, W21, or W22
wherein the radicals A, B, D and R w 1 independently, and in each case independently of their respective occurrence, may have one of the meanings stated below:
A: is halogen, NH 2 , CN, CF 3 , OCF 3 , OCHF 2 , COOH, O—CH 2 —COOH, SH, O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, or in each case optionally substituted O—R A 1 , CO—R A 1 , S—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , SO 2 —NR A 2 R A 3 , or CO—NR A 2 R A 3 ;
R A 1 : is in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl, or benzyl;
R A 2 ; R A 3 , independently stand for
hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, phenyl, benzyl, phenethyl, CO—C 1 -C 6 alkyl, CO-aryl, CO—O—C 1 -C 6 alkyl, SO 4 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, or SO 2 —C 1 -C 4 alkyene-aryl; or both radicals R A 2 and R A 3 together with the nitrogen form a 5- or 6-membered saturated or aromatic ring which is optionally substituted in each case, and which may contain one or two heteroatoms, which may be the same or different, selected from the group comprising O and N;
R A 4 : is hydrogen or an optionally substituted C 1 -C 6 alkyl radical;
B: is hydrogen, halogen, CN, CF 3 —CHF 2 , OCF 3 , OCHF 2 , or in each case optionally optionally substituted C 1 -C 6 alkyl or C 2 -C 6 alkenyl, or in each case substituted —O—CH 2 —COO—R A 1 , —O—R A 1 , S—R A 1 , NRA 2 RA 3 , —NR A 4 —CO—R A 1 , or CO—NRA 2 RA 3 ; NRA 4 —SO 2 —RA 2 ; or B together with R w 1 forms one of the radicals —(CH 2 ) 3 —, —O—CH 2 —O—, —O—(CH 2 ) 2 —O—, —CH═CH—CH═CH—, —O—(CH 2 ) 2 —O—, —CH═CH—CH═CH—, —O—(CH 2 ) 2 —, or —(CH 2 ) 2 —O—;
R w 1 : is hydrogen F, Cl, CN, CF 3 , O—CF 3 , or in each case optionally substituted C 1 -C 6 alkyl, aryl, C 1 -C 6 alkylamino, or C 1 -C 6 dialkylamino;
D: is hydrogen or, independently from A, is defined the same way as radical A.
6 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , R Q 5 , R Q 5* , R Q 6 , R Q 7 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
R 1 , R 2 independently stand for:
hydrogen, OH, CN, C 1 -C 6 alkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, substituted aryl, benzyl, CO—C 1 -C 6 alkyl, CO-aryl, or CO—C 1 -C 4 alkylene-aryl;
R 3 is a free electron pair or hydrogen.
7 . A 5-ring heteroaromatic compound or general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
X, Y, Z
X=N, Y=CR 4 , Z=CR 6 , or
X=C, Y=NR 4 , Z=CR 7 , or
X=N, Y=N, CR 6 .
8 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
X, Y, Z
X=N, Y=CR 4 , Z=CR 6 , or
X=N, Y=N, Z=CR 6 .
9 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
R 4 , R 6 in each case independently stand for a radical, selected from groups 1.), 3.), 4.), or 5. ), which may be the same or different, and
R 5 , R 7 in each case independently stand for a radical selected from groups 2.), 3.), 4.), or 5. ), which may be the same or different,
wherein groups 1.), 2.), 3.), 4.), and 5.) are defined as follows:
1.) Hydrogen, CN, CF 3 , CHF 2 , O—CH 2 —COOH, halogen, or
in each case optionally substituted C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, or no each case optionally substituted
—O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—R Z,Y 5 , NR Z,Y 7 —CO—O—R Z,Y 5 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 6 , SO 4 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ;
2.) A free electron pair or hydrogen,
in each case optionally substituted C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, COO—C 1 -C 6 alkyl, or in each case optionally substituted SO—R Z,Y 5 , SO 2 NH 2 , SO 2 −NR Z,Y 6 R Z,Y 7 or CO—NR Z,Y 6 R Z,Y 7 ;
3.) Phenyl, 1-naphthyl, or 2-naphthyl, in each case substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 , wherein
R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 in each case independently represent a substituent from the following group:
Hydrogen, NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , O—CH 2 —COON, halogen, or in each case optionally substituted aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
—O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 —CO—O—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 ,N Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 , or
in each case two of the radicals selected from R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 form, together with the ring atoms bearing these substituents, a 3- to 7-membered saturated or unsaturated carbocycle which in each case is optionally substituted, or a saturated or unsaturated heterocycle which in each case is optionally substituted and which may contain one, two, or three further heteroatoms, which may be the same or different, selected from the group comprising O, N, and S;
R Z,Y 4 is in each case optionally substituted C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, hetaryl, aryl, C 1 -C 4 alkylene-hetaryl, hetaryl, C 1 -C 4 alkylene-aryl, or
C 1 -C 6 alkyl, which in each case is optionally substituted with a substituent selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NH—(C 1 -C 6 alkyl), and N(C 1 -C 6 alkyl) 2 ;
R Z,Y 5 is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, or C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, or dioxymethylenephenyl, or aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted with substituents independently selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NH—(C 1 -C 6 alkyl) or N(C 1 -C 6 alkyl) 2 , COOH, O—CH 2 —COOH, SH, or in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, hetaryl, heterocycloalkyl, or in each case optionally substituted
—O—R A 1 , S—R A 1 , NR A 4 —CO—O—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , SO 2 —R A 3 , NR A 4 —SO 2 —R A 1 , SO 4 —NR A 2 R A 3 ;
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 6 alkylene-hetaryl, —CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -aryl, SO 2 -hetaryl, SO 2 -C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
R Z,Y 6 is hydrogen or in each case optionally substituted C 1 -C 6 alkyl,
or the radicals R Z,Y 6 and R Z,Y 7 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle which is optionally substituted in each case, which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S;
4. ) 5- or 6-membered aromatic heterocycle which may contain one, two, or three heteroatoms selected from the group
comprising O, N, and S, and which in each case may be substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 ;
5.) A C 5 -C 10 bi- or tricyclic saturated hydrocarbon radical which is optionally substituted.
10 . A 5-ring heteroaromatic compound of general formula according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stared in claim 1 , and the radicals below have the following definitions:
W: is a radical of the general formula
[wherein]
A: is F, Cl, OCF 3 , OCHF 2 , in each case optionally substituted C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, or OR A 1 ;
B: is hydrogen, F, Cl, CF 3 , OCF 3 , OCHF 2 , in each case optionally substituted C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, or S—C 1 -C 6 alkyl;
R w 1 : is hydrogen, F, Cl, CN, CF 3 , or O—CF 3 ;
R A 1 : C 1 -C 6 alkyl or phenyl optionally substituted in each case.
11 . ) A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, R 1 , R 2 , R 3 , XYZ, R 4 , R 5 , R 6 , R 7 , R Z,Y 3 , R Z,Y 4 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
Q: is —CR Q 1 R Q 2 —;
R Q 1 , R Q 2 , in each case independently stand for hydrogen, F, or CH 3 .
12 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2, R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
R 1 , R 2 independently stand for:
hydrogen, OH, CN, O-methyl, O-phenyl, acetyl, benzoyl, O-acetyl, or O-benzoyl;
R 3 is a tree electron pair or hydrogen.
13 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2, R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , X, Y, Z, R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, has the same meaning stated in claim 1 , and the radicals below have the following definitions:
R 1 , R 2 are hydrogen;
R 3 is a free electron pair or hydrogen.
14 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereometic, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2, R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
X, Y, Z
X=N, Y=CR 4 , Z=CR 6 .
15 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2, R A 3 , R A 4 , B, D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, unless stated otherwise below, have the same meaning stated in claim 1 , and the radicals below have the following definitions:
R 4 , R 6 in each case independently stand for a radical, selected from groups 1. ), 3.), 4.) or 5.), which may be the same or different, and
R 5 , R 7 is a radical selected from groups 2.) or 3.), which may be the same or different, wherein groups 1.), 2.), 3.), 4.), and 5.) are defined as follows:
Hydrogen, CF 3 , CHF 2 , or
in each case optionally substituted C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
NR Z,Y 7 —CO—O—R Z,Y 5 , SO—R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 or CO—NR Z,Y 6 R Z,Y 7 ;
2.) A free electron pair or hydrogen, or
in each case optionally substituted C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl;
3.) Phenyl or naphthyl, in each case substituted with R Z,Y 1 ,
R Z,Y 2 , and R Z,Y 3 , wherein R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 in each case independently represent a substituent from the following group:
Hydrogen, CN, NH 2 , CF 3 , OCF 3 , OCHF 2 , O—CH 2 —COOH, halogen, or in each case optionally substituted aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or in each case optionally substituted
O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , SO 2 —NR Z,Y 6 R Z,Y 7 , or N Z,Y 7 SO 2 —R Z,Y 5 , or in each case two of the radicals from R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 form, together with the ring atoms bearing these substituents, a 3- to 7-membered saturated or unsaturated carbocycle which in
each case is optionally substituted, or a saturated or unsaturated heterocycle which in each case is optionally substituted and which may contain one, two, or three further heteroatoms selected from the group comprising O, N, and S;
wherein
R Z,Y 4 in each case is an optionally substituted hetaryl, aryl, or
C 1 -C 6 alkyl which in each case is optionally substituted with a substituent selected from the group comprising halogen, CN, CF 3 , CHF 2 , OCF OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl), and optionally substituted N(C 1 -C 6 alkyl);
R Z,Y 5 in each case is an optionally substituted C 1 -C 6 alkyl, or
aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted with substituents independently selected from the group comprising halogen, NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NH—(C 1 -C 6 alkyl), or N(C 1 -C 6 alkyl) 2 , or optionally substituted C 1 -C 6 alkyl, or in each case optionally substituted O—R A 1 , NR A 2 R A 3 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , or SO 2 —NR A 2 R A 3 ;
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, aryl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, or SO 2 —C 1 -C 4 alkylene-aryl;
R Z,Y 7 is hydrogen or in each case optionally substituted C 1 -C 6 alkyl;
or the radicals R Z,Y 6 and R Z,Y 7 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle which is optionally substituted in each case and which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S;
4. ) A 5- or 6-membered aromatic heterocycle which may contain one, two, or three heteroatoms, which may be different or the same, selected from the group comprising O, N, and S, and which in each case may be substituted with R Z,Y 2 , and R Z,Y 3 as defined above;
5.) Optionally substituted adamantyl.
16 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 4 , R 5 , R 6 , R 7 , R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , R Z,Y 4 , R Z,Y 5 , R Z,Y 6 , R Z,Y 7 , R Z,Y 8 , unless stated otherwise below, have the following definitions:
W: is a radical of the general formula
[wherein]
A: is NH 2 , OCF 3 , OCHF 2 , COOH, O—CH 2 —COOH, SH, or in each case
optionally substituted O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, C 1 -C 6 alkyl, or in each case optionally substituted
O—R A 1 , CO—R A 1 , S—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , SO 2 —NRA 2 R A 3 , or CO—NR A 2 R A 3 ; wherein
R A 1 : is in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl, or benzyl;
R A 2 ; R A 3 independently stand for
hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, phenyl, benzyl, phenethyl, CO—C 1 -C 6 alkyl, CO-aryl, CO—O—C 1 -C 6 alkyl, SO 2 —C 1 -C 6 alkyl, SO 2 aryl, SO 2 -hetaryl, or SO 2 —C 1 -C 4 alkylene-aryl; or both radicals R A 2 and R A 3 together with the nitrogen form a 5- or 6-membered saturated or aromatic ring which is optionally substituted in each case, and which may contain one or two further heteroatoms, which may be the same or different, selected from the group comprising O and N;
R A 4 : is hydrogen or an optionally substituted C 1 -C 6 alkyl radical;
B: is hydrogen, halogen, CN, CF 3 , —CHF 2 , OCF 3 , OCHF 2 , or in each case optionally substituted C 1 -C 6 alkyl or C 2 -C 6 alkenyl, or in each case optionally substituted —O—CH 2 —COO—R A 1 , —O—R A 1 , S—R A 1 , NR A 2 R A 3 , —NR A 4 —CO—R A 1 , or —CO—NRA 2 R A 3 ; NRA 4 —SO 2 —R A 1 ; or B together with R w 1 forms one of radicals —(CH 2 ) 3 —, —O—CH 2 —O—, —O—(CH 2 ) 2 —O—, —C═CH—CH═CH—, —O—(CH 2 ) 2 —, or —(CH 2 ) 2 —O—;
R 1 1 : is hydrogen, F, Cl, CN, CF 3 , O—CF 3 , or
in each case optionally substituted C 1 -C 6 alkyl, aryl, C 1 -C 6 alkylamino, or C 1 -C 6 dialkylamino;
Q: in formula Q1 is the sum of a, b, and c, which is equal to 1, 2, or 3;
R Q 1 , R Q 2 , R Q 3 , R Q 4 independently stand for:
hydrogen, halogen, OH, optionally substituted C 1 -C 6 alkyl;
V Q : is —CO—, —CO—NR Q 5 —, NR Q 5 —CO—, —O—, —S—;
R Q 5 : is hydrogen, CH 3 ;
R 1 , R 2 independently stand for:
hydrogen, OH, CN, or in each case optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, substituted aryl, benzyl, CO—C 1 -C 6 alkyl, CO-aryl, or CO—C 1 -C 6 alkylene-aryl;
R 3 is a free electron pair or hydrogen;
X, Y Z
X=N, Y=CR 4 , Z=CR 6 , or
X=C, Y=CR 4 , Z=NR 7 , or
X=N, Y=N Z=CR 6 ;
R 4 , R 6 in each case independently stand for a radical, selected from coups 1.), 3.), 4.), or 5.), which may be the same or different, and
R 5 , R 7 in each case independently stand for a radical selected from groups 2.), 3.), 4.), or 5.), which may be the same or different, wherein groups 1.) through 5.) have the following meanings:
1.) Hydrogen, CN, CF 3 , CHF 2 , O—CH 2 —COON, halogen, or in each
case optionally substituted C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—OR Z,Y 5 , NR Z,Y 7 —CO—O—R Z,Y 5 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ;
2. A free electron pair or hydrogen,
in each case optionally substituted C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, COO—C 1 -C 6 alkyl, or SO—R Z,Y 5 , SO 2 NH 2 , or in each case optionally substituted SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ;
3.) Phenyl, 1-naphthyl, or 2-naphthyl, which in each case are or may be substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 , wherein
R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 in each case it represent a substituent selected from the following group:
Hydrogen, NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , O—CH 2 —COON, halogen, or in each case optionally substituted aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
O—R Z,Y 4 , S—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , R Z,Y 7 —CO—OR Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , CO 2 NH 2 , or CO—NR Z,Y 6 R Z,Y 7 , or
in each case two of the radicals from R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 form, together with the ring atoms bearing these substituents, a 3- to 7-membered saturated or unsaturated carbocycle which in each case is optionally substituted, or a saturated or unsaturated heterocycle which in each case is optionally substituted and which may contain two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S;
R Z,Y 4 is in each case optionally substituted C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, hetaryl, aryl, C 1 -C 4 alkylene-hetaryl, hetaryl, C 1 -C 4 alkylene-aryl, or
C 1 -C 6 alkyl which in each case i optionally substituted with a substituent selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl), and optionally substituted N(C 1 -C 6 alkyl) 2 ;
R Z,Y 5 is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, or C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, or dioxymethylenephenyl, or aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted with substituents independently selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl) or optionally substituted N(C 1 -C 6 alkyl) 2 , COOH, O—CH 2 —COOH, SH, or
optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, hetaryl, heterocycloalkyl, or
O—R A 1 , S—R A 1 , NR A 4 —CO—O—R A 1 , O—CH 2 —COO—R A 1 , NR A 2 R A 3 , CONH 2 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , or SO 2 —NR A 2 R A 3 ;
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, CO-aryl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—C 1 -C 6 alkyl, CO—O-aryl, CO—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—C 1 -C 4 alkylene-hetaryl, CO—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 —C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
R X,Y 7 is hydrogen or in each case optionally substituted C 1 -C 6 alkyl;
or the radicals R Z,Y 6 and R Z,Y 7 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle, which is optionally substituted in each case and which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S;
4.) A 5- or 6-membered aromatic heterocycle which may contain one, two, or three heteroatoms, which may be different or the same, selected from the group comprising O, N, at S and which in each case may be substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 as defined above;
5.) A C 5 -C 10 bi- or tricyclic saturated hydrocarbon radical which is optionally substituted in each case.
17 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, A, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, unless stated otherwise below, have the following definitions;
W: is a radical of the general formula
[wherein]
A: is F, Cl, OCF 3 , OCHF 2 , in each case optionally substituted C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl, or optionally substituted OR A ;
R A 1 : is in each case optionally substituted C 1 -C 6 alkyl or phenyl;
B: is hydrogen, F, Cl, CF 3 , OCF 3 , OCHF 2 , or in each case optionally substituted C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, S—C 1 -C 6 alkyl;
R w 1 : is hydrogen, F, Cl, CN, CF 3 , or O—CF 3 ;
Q: is —CR Q 1 R Q 2 —;
R Q 1 , R Q 2 in each case independently stand for hydrogen, F, CH 3 ;
R 1 , R 2 independently stand for:
hydrogen, OH, CN, O-methyl, O-phenyl, acetyl, benzoyl, O-acetyl, O-benzoyl;
R 3 is a free electron pair or hydrogen;
X, Y, Z
X=N, Y=CR 4 , Z=CR 6 , or
X=N, Y=N, Z=CR 6 ;
R 4 , R 6 in each case independently stand for a radical, selected from groups 1.), 3.), 4.), or 5.), which may be the same or different, and
R 5 is a radical selected from groups 2.) or 3.), which may be the same or different, wherein groups 1.) through 5.) have the following meanings:
1.) Hydrogen, CN, CF, CHF 2 , O—CH 2 —COOH, halogen, or in each case optionally substituted C 1 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , CO—OR Z,Y 6 , NR Z,Y 7 —CO—O—R Z,Y 6 , O—CH 2 —COO—R Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 6 , SO 2 R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , CONH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 R Z,Y 7 ;
2.) A free electron pair or hydrogen,
in each case optionally substituted C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, COO—C 1 -C 4 alkyl, or SO—R Z,Y 5 , SO 2 NH 2 , CONH 2 , optionally substituted SO 2 —NR Z,Y 5 R Z,Y 7 , or optionally substituted CO—NR Z,Y 6 R Z,Y 7 ;
3.) Phenyl, 1-napthyl, or 2-naphthyl, which in each case may substituted with R Z,Y 1 R Z,Y 2 , and R Z,Y 3 , and wherein
R Z,Y 1 R Z,Y 2 , and R Z,Y 3 in each case independently represent a substituent from the following group:
Hydrogen, NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , O—CH 2 —COOH, halogen, or in each case optionally substituted aryl, hetaryl, heterocycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, C 1 -C 4 alkylene-aryl, or C 1 -C 4 alkylene-hetaryl, or in each case optionally substituted
O—R Z,Y 4 , S—R Z,Y 4 , N Z,Y 6 R Z,Y 7 , NR 4 Y 6 R Z,Y 7 —CO—OR Z,Y 5 , NR Z,Y 7 —CO—R Z,Y 5 , SO 2 —R Z,Y 5 , NR Z,Y 7 —SO 2 —R Z,Y 5 , SO 2 NH 2 , SO 2 —NR Z,Y 6 R Z,Y 7 , or CO—NR Z,Y 6 , R Z,Y 7 , or
in each case two of the radicals from R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 form, together with the ring atoms bearing these substituents, a 3- to 7-membered saturated or unsaturated carbocycle which in each case is optionally substituted, or a saturated or unsaturated heterocycle which in each case is optionally substituted and which may contain one, two, or three further heteroatoms selected from the group comprising O, N, and S;
R Z,Y 4 in each case is an optionally substituted C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, hetaryl, aryl, C 1 -C 4 alkylene-hetaryl, hetaryl, C 1 -C 4 alkylene-aryl, or
C 1 -C 6 alkyl which in each case is optionally substituted with a substituent selected from the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl), and optionally substituted N(C 1 -C 6 alkyl) 2 .
R Z,Y 5 is in each case optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-heterocycloalkyl, heterocycloalkyl, or C 1 -C 6 alkylene-O—C 1 -C 6 alkyl,
or dioxymethylenephenyl, or aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted with substituents independently selected From the group comprising halogen, NO 2 , NH 2 , OH, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl)
or optionally substituted N(C 1 -C 6 alkyl) 2 , COOH, O—CH 2 —COOH, SH, or in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, hetaryl, heterocycloalkyl, or in each case optionally substituted
O—R A 1 , S—R A 1 , NR A 4 —CO—O—R A 1 , O—CH 2 R A 1 , NR A 2 , R A 3 , CONH 2 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , or SO 2 —NR A 2 R A 3 ;
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 cycloyalkyl, C 1 -C 4 alkylene-heterocycloalkyl, aryl, hetaryl, heterocycloyalkyl, C 1 -C 6 alkylene-O—C 1 -C 6 alkyl, CO—C 1 -C 6 alkyl, C 1 -C 4 alkylene-aryl, C 1 -C 4 alkylene-hetaryl, CO-aryl, CO-hetaryl, CO—C 1 -C 4 alkylene-aryl, CO—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 6 alkyl, CO—O-aryl, CO—O—C 1 -C 4 alkylene-aryl, CO—O-hetaryl, CO—O—C 1 -C 4 alkylene-hetaryl, CO—O—C 1 -C 4 alkylene-aryl, SO 2 —C 1 -C 6 alkyl, SO 2 -aryl, SO 2 -hetaryl, SO 2 -C 1 -C 4 alkylene-aryl, or SO 2 —C 1 -C 4 alkylene-hetaryl;
R Z,Y 7 is hydrogen or optionally substituted C 1 -C 6 alkyl;
or the radicals R Z,Y 6 and R Z,Y 7 together with the nitrogen form a 3- to 7-membered saturated or aromatic heterocycle which is optionally substituted in each case and which may contain one, two, or three further heteroatoms, which may be different or the same, selected from the group comprising O, N, and S;
4.) A 5- or 6-membered aromatic heterocycle which may contain one, two, or three heteroatoms, which may be different or the same, selected from the group comprising O, N, and S, and which in each case may be substituted with R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 as defined above;
5.) Optionally substituted adamantyl.
18 . A 5-ring heteroaromatic compound general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals W, R A 1 , R A 2 , R A 3 , R A 4 , B, R w 1 , D, Q, a, b, c, R Q 1 , R Q 2 , R Q 3 , R Q 4 , V Q , R Q 5 , R Q 5* , R Q 6 , R Q 7 , R 1 , R 2 , R 3 , X, Y, Z, unless stated otherwise below, have the following definitions:
W: is a radical of the general formula
[wherein]
A: is OCF 3 , OCHF 2 , OCH 3 , methyl, O-ethyl, O-propyl, or O-isopropyl;
B: is hydrogen, F, Cl, CF 3 , OCF 3 , OCHF 2 , optionally substituted C 1 -C 6 alkyl, or optionally substituted O—C 1 -C 6 alkyl;
R w 1 : is hydrogen, F, Cl;
Q: is —CH 2 —;
R 1 , R2 are hydrogen;
R 3 is a free electron pair or hydrogen;
X is N;
Y is CR 4 ;
Z is CR 6 ;
R 4 , R 6 in each case independently stand for a radical, selected from groups 1.), 2.), 3.) which may be the same or different, wherein groups 1.) through 3.) mean the following:
1.) Hydrogen, CF 3 , CHF 2 , or in each case optionally substituted C 1 -C 10 alkyl; or
2.) Phenyl, 1-naphthyl, or 2-naphthyl, which in each case are substituted with R Z,Y 2 , and R Z,Y 3 , wherein
R Z,Y 1 , R Z,Y 2 , and R Z,Y 3 in each case independently represent a substituent from the following group:
Hydrogen, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , O—CH 2 —COON, halogen, or in each case optionally substituted C 1 -C 6 alkyl, aryl, or in each case optionally substituted O—R Z,Y 4 , NR Z,Y 6 R Z,Y 7 , NR Z,Y 7 —SO 2 —R Z,Y 6 , or
in each case two of the radicals selected from the group comprising R Z,Y 1 , R Z,Y 2 , or R Z,Y 3 together form one of the radicals
—O—CH 2 —O—, —O—CH 2 —CH 2 —O—, —O—CH 2 —CH 2 —, or —CH 2 —CH 2 —CH 2 —;
R Z,Y 4 is in each case optionally substituted hetaryl, aryl, or C 1 -C 6 alkyl;
R Z,Y 5 is in each case optionally substituted C 1 -C 6 alkyl, or aryl or hetaryl which in each case is optionally singly, doubly, or triply substituted substituents independently selected from the group comprising halogen, NH 2 , CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , optionally substituted NH—(C 1 -C 6 alkyl) or in each case optionally substituted N(C 1 -C 6 alkyl) 2 , or optionally substituted C 1 -C 6 alkyl, or optionally substituted O—R A 1 , NR A 2 R A 3 , SO 2 NH 2 , SO 2 —R A 1 , NR A 4 —SO 2 —R A 1 , or SO 2 —NR A 2 R A 3 ;
R Z,Y 6 is hydrogen, or
in each case optionally substituted C 1 -C 6 alkyl, aryl, SO 2 —C 1 -C 6 alkyl; SO 2 -aryl;
R Z,Y 7 is hydrogen or optionally substituted C 1 -C 6 alkyl
3.) Benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, thienyl, furanyl, pyridinyl, pyrimidinyl, or thiazolyl, which in each case may be substituted with R Z,Y 1 , R Z,Y 2 and R Z,Y 3 .
19 . A 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, wherein the radicals R Z,Y 1 , R Z,Y 2 , R Z,Y 3 , Q, W, X, Y, and Z have the meanings stated in claim 1 , for use as medicaments.
20 . A pharmaceutical composition containing at least one 5-ring heteroaromatic compound of general formula I according to claim 1 , and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceuticals acceptable salts thereof, and/or active substance precursors (“prodrugs”) thereof, and optionally at least one pharmaceutically acceptable carrier and/or diluent.
21 . (canceled)
22 . A method for the treatment and/or prevention of, CNS diseases or CNS-related diseases, which composes administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
23 . A method for the treatment and/or prevention of neuropathological, neuropsychiatric, and/or neurodegenerative disorders, symptoms, and/or dysfunctions, which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautormeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
24 . A method for the treatment and/or prevention of, migraines and/or brain damage, which comprises administering art effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
25 . A method for the treatment and/or prevention of, neuropathological, neuropsychiatric, and/or neurodegenerative diseases selected from the group comprising cerebral ischemia, stroke, epilepsy, and attacks in general, psychoses, schizophrenia, autism, OCD syndrome, cognitive disorders, attention disorders, depression, bipolar and/or unipolar depression, anxiety dementia, senile dementia, Alzheimer's dementia, demyelinating diseases, multiple sclerosis, and brain tumors, which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diasteteomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
26 . A method for the treatment and/or prevention of, diseases selected from the group comprising cerebrovascular disorders, pain, pain-related disorders, dependency, drug-related disorders, amnesia, alcohol abuse, drug abuse, circadian rhythm disorders, and Cushing's syndrome, which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
27 . A method for the treatment and/or prevention of diseases modulated by 5-HT5 receptor activity, and/or for producing a medicament for the treatment and/or prevention of diseases which are modulated by 5-HT5 receptor activity which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.
28 . A method for the treatment and/or prevention of, diseases which are modulated by 5-HT5 receptor activity, and wherein the treatment and/or prevention is based on selectivity for the 5-HT5A receptor, which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance Precursors (prodrugs) to a patient in need thereof.
29 . A method for the treatment and/or prevention of, diseases which are modulated by 5-HT5 receptor activity, and wherein the treatment and/or prevention is based on selectivity for the 5-HT5A receptor with a binding affinity (Ki) of less than or to 600 nM, which comprises administering an effective amount of a compound of claim 1 and/or corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and/or pharmaceutically acceptable salts thereof and/or active substance precursors (prodrugs) to a patient in need thereof.Join the waitlist — get patent alerts
Track US2015183770A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.